Alternatives to Traditional Unit Operations Are Now Available to Alleviate Very Real Logjams Due to the complexity of therapeutic protein purification, downstream bioprocess bottlenecks can arise from ...

Over two-thirds of biopharmaceutical manufacturers now report that their facility is experiencing capacity bottlenecks due to downstream processing. A number of factors continue to converge to create ...

The cell and gene therapy industry will greatly benefit from access to robust, scalable, end-to-end solutions for the production and characterization of native and engineered exosome therapeutics.” — ...

Standards organization says R2v3 certification entails accurately portraying operations of facilities receiving components and materials. SERI says qualifications for a non-R2v3 downstream vendor are ...

Discover how early CMC, process optimization, and formulation strategy drive scalable, commercially viable drugs.

Real-time and in-line accurate measuring of protein (monoclonal antibody, or mAb) concentration has been shown across a wide dynamic range (0–135 g/L) through the ...

LONDON--(BUSINESS WIRE)--Quantzig is one of the world’s leading analytics solutions providers, committed to offering cutting-edge analytics solutions to help organizations institutionalize data-driven ...

“However, the downstream equipment presents a much bigger challenge due to the significant investment required to add capacity to the proofer and oven, if possible at all,” he pointed out. “Another ...